Reports Q3 revenue $1.35B, consensus $1.52B. “In the third quarter, we took important actions to sharpen our focus on structural heart by divesting Critical Care and investing in platforms to impact more patients and position Edwards for sustainable growth,” said Bernard Zovighian, CEO. “Third quarter total company sales growth from continuing operations of 10% reflected strong contributions from both TAVR and our rapidly growing TMTT product group. Results from continuing operations were slightly ahead of our guidance expectations. As we look ahead, we see expanded opportunities to meet the needs of a highly diverse group of patients suffering from aortic stenosis, aortic regurgitation, mitral and tricuspid disease, and structural heart failure.”
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Notable companies reporting after market close
- Edwards Lifesciences options imply 8.1% move in share price post-earnings
- Edwards Lifesciences Corp. (EW) Q3 Earnings Cheat Sheet
- Johnson & Johnson reported strong earnings beat, says Barclays
- December 13, 2024 Deadline: Contact Levi & Korsinsky LLP to Join Class Action Suit Against EW